Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant Shigella sonnei Infections in a Retirement Community—Vermont, 2018
Open Access
- 16 May 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (3) , 455-460
Abstract
In 2018, the Centers for Disease Control and Prevention and the Vermont Department of Health investigated an outbreak of multidrug-resistant Shigella sonnei infections in a retirement community that offered a continuum of care from independent living through skilled nursing care. The investigation identified 24 culture-confirmed cases. Isolates were resistant to trimethoprim-sulfamethoxazole, ampicillin, and ceftriaxone, and had decreased susceptibility to azithromycin and ciprofloxacin. To evaluate clinical and microbiologic response, we reviewed inpatient and outpatient medical records for treatment outcomes among the 24 patients with culture-confirmed S. sonnei infection. We defined clinical failure as diarrhea (≥3 loose stools per day) for ≥1 day after treatment finished, and microbiologic failure as a stool culture that yielded S. sonnei after treatment finished. We used broth microdilution to perform antimicrobial susceptibility testing, and whole genome sequencing to identify resistance mechanisms. Isolates contained macrolide resistance genes mph(A) and erm(B) and had azithromycin minimum inhibitory concentrations above the Clinical and Laboratory Standards Institute epidemiological cutoff value of ≤16 µg/mL. Among 24 patients with culture-confirmed Shigella infection, 4 were treated with azithromycin; all had clinical treatment failure and 2 also had microbiologic treatment failure. Isolates were susceptible to ciprofloxacin but contained a gyrA mutation; 2 patients failed treatment with ciprofloxacin. These azithromycin treatment failures demonstrate the importance of clinical breakpoints to aid clinicians in identifying alternative treatment options for resistant strains. Additionally, these treatment failures highlight a need for comprehensive susceptibility testing and systematic outcome studies, particularly given the emergence of multidrug-resistant Shigella among an expanding range of patient populations.Keywords
This publication has 17 references indexed in Scilit:
- The changing epidemiology of bacillary dysentery and characteristics of antimicrobial resistance of Shigella isolated in China from 2004–2014BMC Infectious Diseases, 2016
- Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional studyThe Lancet Infectious Diseases, 2015
- Case of Shigella flexneri infection with treatment failure due to azithromycin resistance in an HIV-positive patientInfection, 2014
- Identification of acquired antimicrobial resistance genesJournal of Antimicrobial Chemotherapy, 2012
- Macrolide-Resistant Shigella sonneiEmerging Infectious Diseases, 2008
- Antimicrobial Safety: Focus on FluoroquinolonesClinical Infectious Diseases, 2005
- RANDOMIZED COMPARISON OF AZITHROMYCIN VERSUS CEFIXIME FOR TREATMENT OF SHIGELLOSIS IN CHILDRENThe Pediatric Infectious Disease Journal, 2003
- Treatment of Shigellosis: V. Comparison of Azithromycin and Ciprofloxacin: A Double-Blind, Randomized, Controlled TrialAnnals of Internal Medicine, 1997
- Treatment of Shigellosis: III. Comparison of One- or Two-Dose Ciprofloxacin with Standard 5-Day TherapyAnnals of Internal Medicine, 1992
- Therapy for Shigellosis. II. Randomized, Double-Blind Comparison of Ciprofloxacin and AmpicillinThe Journal of Infectious Diseases, 1990